e-learning
resources
Berlin 2008
Tuesday, 07.10.2008
Recent advances in the treatment and pathogenesis of pulmonary diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Influence of thiotriazolin on phlegm cytogram of patients with community acquired pneumonia (CAP)
I. Ilyuk, V. Malenky (Vinnitsa, Ukraine)
Source:
Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Session:
Recent advances in the treatment and pathogenesis of pulmonary diseases
Session type:
E-Communication Session
Number:
4263
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Ilyuk, V. Malenky (Vinnitsa, Ukraine). Influence of thiotriazolin on phlegm cytogram of patients with community acquired pneumonia (CAP). Eur Respir J 2008; 32: Suppl. 52, 4263
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Biological markers in hospitalised patients with community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011
Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Enhanced neutrophil response in patients with chronic bronchitis and community-acquired pneumonia (CAP)
Source: Eur Respir J 2002; 20: Suppl. 38, 418s
Year: 2002
Effect of benzylpenicillin-ciprofloxacin vs. ceftriaxon-ciprofloxacin in treatment of massive pneumonia (CAP-community acquired pneumonia)
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Cardiac diseases in patients with community acquired pneumonia (CAP)
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
Comparison of costs of community-acquired pneumonia (CAP) treatment at patients with and without bronchial obstruction
Source: Annual Congress 2011 - COPD management
Year: 2011
Determinants of vaccination in patients with community acquired pneumonia (CAP) or chronic lung diseases
Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence
Year: 2004
Etiology of community-acquired pneumonia (CAP) in young hospital patients
Source: Eur Respir J 2002; 20: Suppl. 38, 356s
Year: 2002
Hyperglycaemia in children with community acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 318s
Year: 2003
Healthcare-associated pneumonia among hospitalized patients. Is it really different from community acquired pneumonia?
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012
The dynamics of dyspnea in patients (pts) with pneumonia on the background of SARS-CoV2 infection
Source: Virtual Congress 2021 – Respiratory failure in COVID19 and beyond
Year: 2021
Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study)
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005
Influence of medical comorbidities in patients with community acquired pneumonia
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010
The incidence of Q fever in hospitalized patients with community acquired pneumonia
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Clinical stability in patients with community- acquired pneumonia (CAP)
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
Analysis of therapy of community-acquired pneumonia (CAP) at the COPD patients
Source: Annual Congress 2011 - COPD management
Year: 2011
Commonly acquired pneumonia (CAP) in the elderly patients
Source: Eur Respir J 2006; 28: Suppl. 50, 3s
Year: 2006
Prevalence of hyponatremia (HN) in children with community acquired pneumonia (CAP) and its relation to disease severity, outcomes
Source: Virtual Congress 2021 – Acute paediatric respiratory infections
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept